Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes

References

• Vannucchi AM, Guglielmelli P. What are the current treatment approaches for patients with Polycythemia vera and essential thrombocythemia? Hematology. 2017;(1):480–488. doi:10.1182/asheducation-2017.1.480
   Web of Science ®Google Scholar
• Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93:1551–1560. doi:10.1002/ajh.2523030039550
   PubMed Web of Science ®Google Scholar
• Mesa R, Boccia RV, Grunwald MR, et al. Patient-reported outcomes data from REVEAL at the Time of Enrollment (Baseline): a prospective observational study of patients with Polycythemia vera in the United States. Clin Lymphoma, Myeloma Leuk. 2018;18:590–596. doi:10.1016/j.clml.2018.05.02030122202
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of Polycythemia vera. N Engl J Med. 2015;372:426–435. doi:10.1038/mt.2009.26525629741
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167. doi:10.1186/s12885-016-2208-226922064
   PubMed Web of Science ®Google Scholar
• Abelsson J, Andréasson B, Samuelsson J, et al. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma. 2013;54(10):2226–2230.23398206
   PubMed Web of Science ®Google Scholar
• Stein BL, Moliterno AR, Tiu RV. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Ann Hematol. 2014;93:1965–1976. doi:10.1007/s00277-014-2205-y25270596
   PubMed Web of Science ®Google Scholar
• Nelson EC, Eftimovska E, Lind C, et al. Patient reported outcome measures in practice. BMJ. 2015;350:g7818–g7818. doi:10.1136/bmj.g781825670183
   PubMed Web of Science ®Google Scholar
• Buckley SA, Kirtane K, Walter RB, et al. Patient-reported outcomes in acute myeloid leukemia: where are we now? Blood Rev. 2018;32:81–87. doi:10.1016/j.blre.2017.08.01028888621
   PubMed Web of Science ®Google Scholar
• Bryant AL, Drier SW, Lee S, Bennett AV. A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2018;70:106–116. doi:10.1016/j.leukres.2018.06.00629925044
   PubMed Web of Science ®Google Scholar
• Mesa R, Verstovsek S, Kiladjian JJ, et al. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol. 2016;97:192–200. doi:10.1111/ejh.1270726608702
   PubMed Web of Science ®Google Scholar
• Blum S, Martins F, Alberio L. Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. J Blood Med. 2016;7:205–215. doi:10.2147/JBM.S10247127729820
   PubMedGoogle Scholar
• Mesa RA, Miller CB, Mascarenhas JO, et al. Hydroxyurea treatment history and quality of life in patients with polycythemia vera: results from the MPN landmark survey in the United States. Blood. 2015;126(23):4077.
   Google Scholar
• Scherber R, Dueck A, Kiladjian J, et al. Conventional therapeutic options have limited impact on MPN symptoms: insights from a prospective analysis of the MPN-SAF TSS. Haematologica. 2012.
   Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European leukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119:1363–1369. doi:10.1182/blood-2011-10-38778722160617
   PubMed Web of Science ®Google Scholar
• Raedler LA. Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with Polycythemia vera. Am Heal Drug Benefits. 2015;8:75–79.
   PubMedGoogle Scholar
• Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–4781. doi:10.1182/blood-2013-01-47889123591792
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. doi:10.1056/NEJMoa111055722375971
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.22375970
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009;6(6):e1000097. doi:10.1371/journal.pmed119621072
   PubMed Web of Science ®Google Scholar
• Hong QN, Gonzalez-Reyes A, Pluye P. Improving the usefulness of a tool for appraising the quality of qualitative, quantitative and mixed methods studies, the Mixed Methods Appraisal Tool (MMAT). J Eval Clin Pract. 2018;24(3):459–467. doi:10.1111/jep.1288429464873
   PubMed Web of Science ®Google Scholar
• P F, G M, P F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):p. 88–99. doi:10.1016/S1470-2045(16)30558-727916398
   PubMed Web of Science ®Google Scholar
• Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017;176(1):76–85. doi:10.1111/bjh.1438227858987
   PubMed Web of Science ®Google Scholar
• Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–408. doi:10.1182/blood-2011-01-32895521536863
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76. doi:10.1002/cncr.2236517123268
   PubMed Web of Science ®Google Scholar
• Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199–1203. doi:10.1016/j.leukres.2009.01.03519250674
   PubMed Web of Science ®Google Scholar
• Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285–1292. doi:10.1200/JCO.2012.44.448923423753
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–4103. doi:10.1200/JCO.2012.42.386323071245
   PubMed Web of Science ®Google Scholar
• Pourcelot E, Trocme C, Mondet J, et al. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–368. doi:10.1016/j.exphem.2014.01.00624463275
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. N Engl J Med. 2010;363(12):1117–1127. doi:10.1056/NEJMoa100202820843246
   PubMed Web of Science ®Google Scholar
• Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011;117(21):4869–4877. doi:10.1002/cncr.2612921480207
   PubMed Web of Science ®Google Scholar
• Fedratinib becomes new option in myelofibrosis. Cancer Discov. 2019;9(10):1332. doi:10.1158/2159-8290.CD-NB2019-102
   Web of Science ®Google Scholar
• Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol. 2015;1(5):643–51. doi:10.1001/jamaoncol.2015.159026181658
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Courby S, Griesshammer M, et al. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017. doi:10.1016/j.leukres.2017.05.002
   Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25(32):5121–5127.17991931
   PubMed Web of Science ®Google Scholar